Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Tipranavir is the most recently introduced protease inhibitor for the suppression of the human immunodeficiency virus (HIV). A selective reversed-phase liquid chromatographic assay, previously developed for atazanavir, has been extended and validated for tipranavir in plasma. Compounds were isolated from a 500 microL plasma sample using liquid-liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using reversed-phase liquid chromatography and ultra violet detection at 280 nm. In the evaluated concentration range (0.2-50 microg/mL tipranavir), intra-day precisions were <or=8% and inter-day precisions were <or=10%. Accuracies between 95 and 108% were found. The clinical applicability of the assay was demonstrated in an HIV-infected patient who ingested 500 mg tipranavir bid in combination with 100 mg ritonavir.
Sparidans
Rolf W
RW
Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands. r.w.sparidans@pharm.uu.nl
Dost
Frits
F
Crommentuyn
Kristel M L
KM
Huitema
Alwin D R
AD
Schellens
Jan H M
JH
Beijnen
Jos H
JH
D002853:Chromatography, Liquid / Q000379:methods*; D017320:HIV Protease Inhibitors / Q000097:blood*; D006801:Humans; D011725:Pyridines / Q000097:blood*; D011753:Pyrones / Q000097:blood*; D013449:Sulfonamides
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir